Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Biology Teacher Battles PNH

    ... in 2015, he is  grateful that he has responded well to eculizumab (Soliris®) treatment. “I’m incredibly fortunate,” he ... by the language and the pictures and the charts.” Eculizumab has worked well enough for Steve, but he is eager to stay on top of ...

    Patient Chronicle last updated 06/28/2016 - 8:15am.

  2. Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

    ... haemoglobinuria (PNH) in patients with resistance to eculizumab due to complement C5 polymorphisms ...

    Clinical Trial last updated 08/26/2016 - 11:59am.

  3. Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria

    ... blockade through the anti-C5 monoclonal antibody eculizumab . This brief review focuses on two specific aspects of PNH: (1) response to eculizumab, variability of response, and how this new agent has impacted ...

    Research Article last updated 06/07/2016 - 10:56am.

  4. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients

    ... complement regulators. Blockage of the lytic pathway by eculizumab is the only available therapy for PNH patients and shows ... to untargeted inhibition of all complement pathways by eculizumab. Thus, the molecular design of each C3-opsonin targeted complement ...

    Research Article last updated 04/29/2016 - 12:58pm.

  5. Self-injected PNH therapy on the horizon

    ... (PNH), behind intravenous (I.V.) Soliris ( eculizumab , Alexion Pharmaceuticals Inc.), given every other week. Coversin ...

    Article last updated 07/07/2016 - 9:40am.

  6. Local TV covers AAMDSIF Peer Support Networker

    ... decade of being diagnosed.   Fortunately, Soliris ( eculizumab ) is available to treat the condition and according to Joe, ...

    Article last updated 11/28/2016 - 3:21pm.

  7. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going

    ... resulting in erythrocyte lysis. The availability of eculizumab as the first complement inhibitor for clinical use renewed the ... independence in at least half of PNH patients receiving eculizumab, with adequate control of all hemolysis-associated symptoms even in ...

    Research Article last updated 05/22/2014 - 8:24am.

  8. Fighting PNH While Helping PNH Patients

    ... went back to my specialist and this wasn’t long after eculizumab (Soliris®) had been approved. I got my first infusion in March ...

    Patient Chronicle last updated 11/21/2016 - 12:47pm.

  9. Complement Blockade with a C1 Esterase Inhibitor in Paroxysmal Nocturnal Hemoglobinuria

    ... context of underlying complement activation. Currently eculizumab effectively blocks the intravascular hemolysis PNH. There ... products on CD55 deficient erythrocytes from PNH patient on eculizumab therapy. This could suggest a role for inhibition of earlier phases ...

    Research Article last updated 08/04/2014 - 8:13am.

  10. Mechanisms and Clinical Implications of Thrombosis in Paroxysmal Nocturnal Hemoglobinuria

    ... the risk, but does not completely prevent thrombosis. Eculizumab , a monoclonal antibody to complement factor C5, ... intravascular hemolysis and also thrombotic risk. As such, eculizumab treatment has dramatically improved the prognosis of PNH. The ...

    Research Article last updated 11/21/2011 - 3:08pm.